Previous Article | Next Article 
J Virol, August 1998, p. 6475-6481, Vol. 72, No. 8
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
The Second Extracellular Loop of CXCR4 Determines Its Function
as a Receptor for Feline Immunodeficiency Virus
Brian J.
Willett,1,*
Karen
Adema,1
Nikolaus
Heveker,2
Anne
Brelot,2
Laurent
Picard,2
Marc
Alizon,2
Julie D.
Turner,3
James A.
Hoxie,3
Stephen
Peiper,4
James C.
Neil,1 and
Margaret J.
Hosie1
Department of Veterinary Pathology,
University of Glasgow Veterinary School, Glasgow G61 1QH, United
Kingdom1;
INSERM U.332, Institute Cochin
de Génétique Moléculaire, 75014 Paris,
France2;
University of Pennsylvania,
Philadelphia, Pennsylvania 191043; and
Department of Pathology, James Graham Brown Cancer Center,
University of Louisville, Louisville, Kentucky 402024
Received 19 March 1998/Accepted 5 May 1998
 |
ABSTRACT |
The feline homolog of the
-chemokine receptor CXCR4 has recently
been shown to support cell-cell fusion mediated by CXCR4-dependent strains of human immunodeficiency virus (HIV) and strains of feline immunodeficiency virus (FIV) that have been selected for growth in the
Crandell feline kidney (CrFK) cell line. In this report we demonstrate
that expression of CXCR4 alone is sufficient to render cells from
diverse species permissive for fusion with FIV-infected cells,
suggesting that CXCR4 is the sole receptor for CrFK-tropic strains of
FIV, analogous to CD4-independent strains of HIV-2. To identify the
regions of CXCR4 involved in fusion mediated by FIV, we screened panels
of chimeric CXCR4 molecules for the ability to support fusion with
FIV-infected cells. Human CXCR4 supported fusion more efficiently
than feline CXCR4 and feline/human CXCR4 chimeras, suggesting that the
second and third extracellular loops of human CXCR4 contain a critical
determinant for receptor function. Rat/human CXCR4 chimeras suggested
that the second extracellular loop contained the principal determinant
for receptor function; however, chimeras constructed between human
CXCR2 and CXCR4 revealed that the first and third loops of CXCR4
contribute to the FIV Env binding site, as replacement of these domains
with the corresponding domains of CXCR2 rendered the molecule
nonfunctional in fusion assays. Mutation of the DRY motif and the
C-terminal cytoplasmic tail of CXCR4 did not affect the ability of the
molecule to support fusion, suggesting that neither signalling via G
proteins nor receptor internalization was required for fusion mediated
by FIV; similarly, truncation of the N terminus of CXCR4 did not affect the function of the molecule as a receptor for FIV. CXCR4-transfected feline cells were rendered permissive for infection with both the
CrFK-tropic PET isolate of FIV and the CXCR4-dependent RF strain of
HIV-1, and susceptibility to infection correlated well with ability to
support fusion. The data suggest that the second extracellular loop of
CXCR4 is the major determinant of CXCR4 usage by FIV.
 |
INTRODUCTION |
The initial stage in infection with
human immunodeficiency virus (HIV) involves an interaction between the
viral envelope glycoprotein (Env) and CD4 on the surface of the target
cell. However, fusion of the viral envelope and the plasma membrane of
the target cell requires a further interaction between Env and a
member of the seven-transmembrane domain (7TM) superfamily of
G-protein-coupled receptors. Strains of HIV that form syncytia with the
MT-2 cell line (27), formerly classified as
syncytium-inducing (SI) strains, have subsequently been shown to
interact with the
-chemokine receptor CXCR4 (21), while
strains of the virus that fail to form syncytia with MT-2 cells
(non-syncytium-inducing [NSI] strains) interact predominantly with
the
-chemokine receptor CCR5 (2, 9, 15, 17,
18). Subsequent studies demonstrated that additional members of
the 7TM superfamily were able to support infection with HIV, and in
some cases simian immunodeficiency virus (SIV), including additional
-chemokine receptors such as CCR2b and CCR3 (9, 17, 43,
47), the receptor encoded by human cytomegalovirus US28
(41), and the orphan receptors STRL33/Bonzo (16,
30), BOB/GPR15 (16, 22), V28 (42, 43), and
GPR1 (34). Previous studies have demonstrated that SI
variants of HIV appear with disease progression (27, 28, 45)
and that the switch to an SI phenotype is accompanied by an increase in
the net charge of the V3 loop (14). The discovery that 7TM
molecules act as coreceptors for HIV infection has provided a molecular
basis for the NSI-to-SI switch. The nature of the coreceptor used by
HIV for infection alters with disease progression (5, 11);
in early infection CCR5-dependent viruses predominate, while in late
infection CXCR4-dependent viruses are more abundant (11).
Similarly, the alterations in the V3 loop that generate an SI phenotype
select for usage of CXCR4 as a coreceptor (9, 48). The
differential usage of chemokine receptors for infection by HIV has
prompted the adoption of a new nomenclature in which the nature of the
chemokine receptor used by the virus defines the phenotype of the
virus: a virus using a CXC receptor would receive the suffix "X,"
while a virus using a CC receptor would receive the suffix "C"
(4). Thus, an SI virus may be defined as X4, for CXCR4
usage, whereas an NSI virus may be defined as C5, for CCR5 usage.
Variants of feline immunodeficiency virus (FIV) that are able to infect
and induce cell fusion in the Crandell feline kidney cell line
(CrFK) use the chemokine receptor CXCR4 as cofactor for infection
(54, 55). Furthermore, such CrFK-tropic viruses display an
increase in charge of the V3 loop (46, 52), analogous to the
changes observed in the V3 loop of HIV with the switch from an NSI to
an SI phenotype (14). Infection with CrFK-tropic strains of
FIV resembles CD4-independent infection with HIV type 2 (HIV-2).
CD4-independent infection with HIV-2 is mediated by CXCR4,
transfection of cells from diverse species with CXCR4 alone renders
them susceptible to infection, and infection is inhibited by the
anti-CXCR4 antibody 12G5 (20). Moreover, the envelope glycoprotein from CXCR4-dependent strains of HIV interacts directly with CXCR4 on CD4-negative cells (23). In comparison, human cells are rendered permissive for fusion with FIV-infected cells by transfection with CXCR4 (55), and the envelope
glycoprotein from a CrFK-tropic strain of FIV competes with stromal
cell-derived factor 1 for binding to feline CXCR4 (25).
The interaction between HIV and CXCR4 has been investigated by using a
series of chimeric CXCR4 molecules. In studies using chimeric molecules
generated between CXCR4 and the related
-chemokine receptor CXCR2,
the first and second extracellular loops of CXCR4 were found to be
important determinants of the interaction with T-cell-tropic or
dualtropic strains of HIV (32). Macrophage-tropic strains
could use CXCR4 only when the amino terminus was replaced with that of
CCR5 (32). The principal determinant of CXCR4 usage by HIV
appeared to be the second extracellular loop in that replacement of the
first and third extracellular loops with the corresponding regions of
CXCR2 generated molecules that retained the ability to support fusion
mediated by some strains of HIV, albeit with a reduced efficiency
(32). When chimeras were generated between human
CXCR4 and rat CXCR4, similar findings were observed in that the
second extracellular loop of CXCR4 was shown to be the
key determinant of CXCR4 usage by the NDK strain of HIV-1
(6). Furthermore, chimeras constructed between murine
and human CXCR4 have demonstrated that the second loop of human CXCR4
expressed in the context of murine CXCR4 renders canine
thymocytes susceptible to infection with HIV-1 strains that are
unable to use murine CXCR4 as a receptor (39).
In this study, we investigated the interaction between FIV and
CXCR4. We demonstrate that CXCR4 is sufficient to render cells susceptible to both fusion and infection with a CrFK-tropic
strain of FIV. Furthermore, using feline CXCR4/human CXCR4, human
CXCR2/human CXCR4, and human CXCR4/rat CXCR4 chimeras, we show that the
fusogenic determinant consists of a discontinuous epitope formed by the first, second, and third extracellular loops of CXCR4 with the second
extracellular loop containing the major determinant of receptor
function. Thus, despite their evolutionary divergence, FIV and
HIV appear to use similar mechanisms to interact with CXCR4.
The results suggest that a conserved structural feature exists in
the envelope glycoproteins of both HIV and FIV and that this enables
the viruses to bind specifically to CXCR4.
 |
MATERIALS AND METHODS |
Antibodies and reagents.
All culture media and supplements
were obtained from Life Technologies, Paisley, United Kingdom.
Cell lines and viruses.
U87-T4 cells expressing human CXCR4
or CCR5 (U87-T4/huCXCR4 or U87-T4/huCCR5 cells) were obtained from Dan
Littman, Skirball Institute for Biomolecular Medicine, New York
University Medical Center. U87 and CrFK cells were maintained in
Dulbecco's modification of minimal essential medium supplemented
with 10% fetal bovine serum (FBS), 2 mM glutamine, sodium
pyruvate (0.11 mg/ml), penicillin (100 IU/ml), and streptomycin (100 µg/ml) (DMEM). The culture media for U87-T4/huCXCR4 and U87-T4/huCCR5
cells were supplemented with puromycin (1 µg/ml; Sigma) and G418 (400 µg/ml; Geneticin, Life Technologies). The CrFK-tropic virus
FIVPET was prepared from a culture of CrFK cells
persistently infected with FIVPET. CrFK cells persistently
infected with the Petaluma (FIVPET) and Glasgow 8 (FIVGL8) isolates of FIV were generated by coculture of
CrFK cells with concanavalin A-stimulated feline peripheral blood
mononuclear cells infected with the Glasgow 8 and Petaluma isolates of
FIV.
Plasmids.
The feline CXCR4/human CXCR4 chimeras were
generated by using the HincII site (nucleotide 421 of
GenBank entry X71635) of human CXCR4, corresponding to the third
transmembrane domain, and the equivalent HincII site
at nucleotide 377 of feCXCR4.pcDNA3 (GenBank entry U63558). As feline
CXCR4 has a second HincII site at position 523, the
appropriate fragments of feline CXCR4 were selected from a
HincII partial digest of feCXCR4.pcDNA3. The nucleic
acid sequences of the chimeric constructs H5F3 and F5H3 were confirmed
by sequencing using Sequenase (Amersham Ltd.). The rat/human CXCR4 and
human CXCR2/CXCR4 chimeras have been described previously (6,
32) and were obtained from Stephen Peiper, James Graham Brown
Cancer Center, University of Louisville. Bonzo and BOB plasmids were
obtained from Dan Littman; GPR1 and GPR15 were from Brian O'Dowd,
University of Toronto; CCR1, -2b, -3, -4, and -5, CXCR1 and -2, EBI1
(42), and V28 (42) were obtained from Jacquie
Reeves, Chester Beatty Laboratories, London, United Kingdom. Feline
CCR5 was a generous gift from John Elder, The Scripps Research
Institute, La Jolla, Calif. The molecular cloning and characterization
of feline CCR5 by using the rapid amplification of cDNA ends technique
will be described elsewhere (29).
Cell fusion assays.
Fusion assays were performed between
FIV-infected CrFK cells and cells transfected with feline or human
chemokine receptors. Cells to be transfected were seeded in six-well
cell culture plates at 1 × 105 to 1.5 × 105 per well in DMEM and allowed to adhere overnight. The
cells were then washed twice with serum-free DMEM, and the medium was
replaced with Opti-MEM (Life Technologies) containing 2 µg of plasmid
DNA and 5 µl of LipofectAMINE (Life Technologies) at 1 ml per well. The cells were incubated with the plasmid-LipofectAMINE mix for 4 h, after which 1 ml of DMEM containing 20% FBS and no antibiotics was
added and the cells cultured overnight. The medium was then aspirated
and replaced with DMEM containing 10% FBS and no antibiotics. The
transfected cells were cultured for a further 24 h, trypsinized, and then seeded in 24-well plates (each well of the original 6-well plate being divided between 4 wells of a 24-well plate) with
FIV-infected CrFK cells at 5 × 104 cells per well.
Fusion was allowed to proceed for 18 to 24 h at 37°C, and then
the cells were fixed and stained with 1% methylene blue-0.2% basic
fuchsin in methanol. Syncytia were enumerated by light microscopy using
a ×12.5 Leitz periplan eyepiece with a 6.5 × 9 graticule, three
separate fields being counted per well, each well in duplicate.
Syncytia were scored as cells with five or more nuclei.
Virus infection assay.
CCC-CD4 cells were seeded at 1.5 × 105 cells per well of six-well tissue culture plates in
DMEM and cultured overnight. The cells were then transfected with 2 µg of plasmid per well in duplicate as described above and cultured
for 48 h, at which time the cells were trypsinized and plated at
5 × 104 cells per well in 24-well tissue culture
plates. After overnight incubation, the cells were infected for 1 h at 37°C with 200 µl of either FIVPET or HIV-1 RF
(approximately 200 pg of reverse transcriptase [RT] per well) and
washed twice with DMEM; then the medium was replaced with 0.5 ml of
DMEM, and the cells were cultured at 37°C. Supernatants were
collected at day 7 postinfection and assayed for
Mg2+-dependent RT activity by using a nonisotopic assay kit
(Lenti-RT kit; Cavidi Tech AB, Uppsala, Sweden). RT levels were
calculated relative to the HIV-1 RT standard provided with the kit.
Nucleotide sequence accession number.
The sequence of feline
CCR5 has been deposited in GenBank under accession no. U92796.
 |
RESULTS |
CXCR4 expression alone is sufficient to confer susceptibility to
fusion mediated by FIV.
Given that CXCR4-transfected human
cells supported fusion mediated by FIV (55), we next asked
whether CXCR4 expression alone was sufficient to render cells from
diverse species permissive for fusion mediated by FIV. The murine cell
line 3T3, hamster cell line CHO, mink cell line Mink S+L-, and
CXCR4-negative feline cell lines CCC and AH927 were transfected
with either feline or human CXCR4 and examined for the
ability to support fusion with FIVPET- and
FIVGL8-infected CrFK cells. Irrespective of the
species of origin, the CXCR4-transfected cells were rendered permissive for fusion with FIV-infected cells, whereas the
CCR5-transfected cells remained refractory to fusion.
CXCR4-transfected feline cells CCC and AH927 (Fig.
1) supported fusion with FIV-infected cells, suggesting that the absence of CXCR4 in these cells lines is the
principal block to infection with CrFK-tropic strains of FIV. Moreover,
the hamster and murine cell lines (CHO and 3T3, respectively) were also
rendered permissive for fusion following transfection with CXCR4
(Fig. 1), suggesting either that a highly conserved component of
the cell surface acts as the primary receptor for CrFK-adapted FIV or
that there is no primary receptor for these viruses and that CXCR4
itself is the viral receptor, analogous to the situation in
CD4-independent infection with HIV-2 vcp (20). We compared
CXCR4 with feline CCR5 (Fig. 1) or human CCR1, CCR2b, CCR3, CCR4, CCR5,
CXCR2, GPR1 (34), GPR15 (22), Bonzo
(16), and BOB (16) and the orphan receptors EBI1
(42) and V28 (42) in the same assay system. In
each case, fusion was detected only in the CXCR4-transfected cells
(data not shown), suggesting that the interaction between FIV and CXCR4
is highly specific. Similar findings were obtained with the CrFK-tropic
variant of FIVGL8.

View larger version (161K):
[in this window]
[in a new window]
|
FIG. 1.
Transfection of cells from diverse species with
CXCR4 renders the cells permissive for fusion with
FIVPET-infected cells. The hamster (CHO), mouse
(3T3), and feline (AH927) cell lines were transfected with either CXCR4
or CCR5, incubated for 48 h, and then trypsinized and seeded with
FIV-infected CrFK cells. Fusion was allowed to progress for 18 h,
at which time the cells were fixed, stained, and photographed.
|
|
The high efficiency of human CXCR4 as a cofactor for FIV-dependent
fusion is mediated by the second extracellular loop.
To map the
determinants of CXCR4 involved in infection with FIV, we compared
feline CXCR4 with human CXCR4 and with chimeric CXCR4 molecules
consisting of the N terminus and first loop of feline CXCR4 fused to
the second and third loops of human CXCR4 (F5H3) or the converse
chimera containing the N terminus and first loop of human CXCR4 fused
to the second and third loops of feline CXCR4 (H5F3). Human CXCR4
consistently proved more fusogenic for FIV Env than feline CXCR4 (Fig.
2). Moreover, the F5H3 chimera supported
fusion with an efficiency similar to that of human CXCR4, while the
H5F3 chimera supported fusion with an efficiency comparable to that of
feline CXCR4. The findings were consistent between at least three
separate experiments. Furthermore, transfection of 0.5 µg of the
green fluorescent protein expression vector GFPN1 in conjunction with
each individual plasmid sample confirmed that the ability of each of
the constructs to confer permissiveness for FIV-mediated fusion could
not be attributed to variability in the relative transfection
efficiencies of the plasmids (data not shown). The data suggest that
the second and third extracellular loops of human CXCR4 contain a
determinant which renders human CXCR4 more fusogenic for FIV Env.

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 2.
Human CXCR4 (huCXCR4) is a more efficient receptor for
FIV than either feline CXCR4 (feCXCR4) or rat CXCR4. CCC-CD4 cells were
transfected with feline, human, or rat CXCR4, the feline/human chimeras
F5H3 and H5F3, or the vector pcDNA3 alone; 48 h posttransfection,
the cells were trypsinized and mixed with FIVPET- or
FIVGL8-infected CrFK cells. Fusion was allowed to proceed
for 18 h, at which time the cells were fixed and stained, and the
number of syncytia per field was quantified by light microscopy.
Results represent the mean number (n = 6) of syncytia
per field ± SE.
|
|
We next asked whether the critical determinant of human CXCR4 for
fusion with FIV Env could be localized specifically to the second or
third extracellular loop. In a previous study (6), a panel
of chimeras between rat and human CXCR4 (Fig.
3a) were screened for the ability to
support fusion mediated by HIV-1. While the CXCR4-dependent strain LAI
used rat and human CXCR4 with comparable efficiencies for CD4-dependent
fusion, replacing the V3 loop of LAI with that of the NDK strain
generated a virus with a marked preference for human CXCR4 over rat
CXCR4; the critical determinant of the preferential usage of human
CXCR4 by HIV-LAI/V3-NDK residing in the second extracellular loop
(6). The feline cell line CCC was transfected with each of
the rat/human CXCR4 chimeras and plated with FIV-infected CrFK cells.
Previous data have demonstrated that the panel of rat/human CXCR4
chimeras are expressed efficiently at the cell surface (6)
following transfection. Furthermore, cotransfection of each of the
plasmids with 0.5 µg of GFPN1 plasmid confirmed that the ability of
each of the constructs to confer permissiveness for FIV-mediated fusion
could not be attributed to variability in the relative transfection
efficiencies of the plasmids (data not shown). Rat CXCR4 supported
fusion less efficiently than either human or feline CXCR4, allowing
good discrimination between the individual loops of human CXCR4 in the
rat CXCR4 background (Fig. 3b). Chimeras A, F, L, and M supported
fusion with an efficiency similar to that of human CXCR4, whereas
chimeras B, G, K and N supported fusion with an efficiency similar to
that of rat CXCR4. Chimera A contains extracellular loops 1, 2, and 3 of human CXCR4, F contains loops 2 and 3, L contains loops 1 and 2, and
M contains the second loop alone in the rat CXCR4 background. Results
represent the mean of six estimations ± standard error (SE).
Pairwise comparisons between plasmids containing either the second loop
of human CXCR4 (A, F, L, M, and human CXCR4) or that of rat CXCR4 (B,
E, G, K, N, and rat CXCR4) demonstrated that those containing the
second extracellular loop of human CXCR4 supported fusion significantly more efficiently than those containing the second loop of rat CXCR4
(P < 0.001 to 0.005). Comparisons within the two
groups of chimeras demonstrated that the human and rat CXCR4 loop 2 constructs supported fusion with similar efficiencies. The data suggest
that the second extracellular loop confers the high capacity for
FIV-dependent fusion to human CXCR4 and that the N terminus and
extracellular loops 1 and 3 can be exchanged with the equivalent
regions of rat CXCR4 without adversely affecting the function of the
molecule.

View larger version (39K):
[in this window]
[in a new window]
|
FIG. 3.
Receptor function of rat/human CXCR4 chimeras
(6) for fusion mediated by FIV. CCC cells were transfected
with a panel of rat/human CXCR4 chimeras (a). Thick lines denote
regions derived from human CXCR4; thin lines denote regions derived
from rat CXCR4. The transfected cells were then assayed for the ability
to support fusion with FIVPET- or
FIVGL8-infected CrFK cells as described above (b). Results
represent the mean (n = 6) number of syncytia per
field ± SE.
|
|
The second loop of CXCR4 alone is insufficient to support
FIV-dependent fusion.
The second extracellular loop of human CXCR4
functioned efficiently in either the feline or the rat CXCR4
background. It is possible that the N terminus and first and third
extracellular loops of rat CXCR4 maintain the second loop of human
CXCR4 in the correct conformation for it to interact with FIV Env.
Therefore, we asked whether it would continue to function as a viral
receptor in chimeras between CXCR4 and human CXCR2 (Fig.
4a). While human and rat CXCR4 show 92%
similarity at the amino acid level, human CXCR4 and CXCR2 show only
50.7% similarity. In a previous study (32), a series of
CXCR2/CXCR4 chimeras was generated and examined for the ability to
support CD4-dependent fusion mediated by HIV Env. While the second
extracellular loop of CXCR4 appeared to be the principal determinant of
CXCR4 usage by HIV, individual strains showed different degrees of
dependence on the N terminus and the first or third extracellular
loops, exchanging these regions with the corresponding regions of CXCR2
severely compromising the function of the molecule as a fusogenic
cofactor. We examined whether CrFK-tropic FIV would tolerate
substitutions in the first and third extracellular loops of CXCR4. CCC
cells were transfected with those members of the panel of CXCR2/CXCR4
chimeras (32) which had been shown to be expressed at the
cell surface following transfection (32) and then plated
with FIV-infected CrFK cells (Fig. 4b). CXCR2 did not support fusion
mediated by FIV. Replacement of the N terminus of CXCR4 with that of
CXCR2 (constructs 2444 and 2444b) did not affect fusion with either
FIVPET- or FIVGL8-infected CrFK cells.
Similarly, truncation of the C-terminal cytoplasmic domain, preventing
internalization of CXCR4 (CXCR4-TAIL), did not affect fusion. Mutation
of the DRY motif (CXCR4-NAA) to generate a molecule that is unable to
couple to G proteins reduced the efficiency of the molecule in the
fusion assay by approximately 60% but did not ablate function
completely, suggesting that signalling via G proteins is not required
for fusion mediated by FIV. Chimeras in which the third extracellular
loop (4442), the N terminus and first extracellular loop (2244), or the
N terminus and first and third extracellular loops (2242) of CXCR4 were
replaced by the corresponding regions of CXCR2 failed to support fusion
mediated by FIV. Given that the first and third loops of human CXCR4
could be replaced with the corresponding regions of rat CXCR4, the
data suggest either that the first and third loops of CXCR4 maintain the second loop in a conformation that is essential for CXCR4 to
support fusion mediated by FIV Env or that all three extracellular loops contribute to the Env binding site.

View larger version (46K):
[in this window]
[in a new window]
|
FIG. 4.
Receptor function of human CXCR2/human CXCR4 chimeras
(32) for fusion mediated by FIV. CCC-CD4 cells were
transfected with the panel of CXCR2/CXCR4 chimeras (a). Thick lines
denote regions derived from CXCR4; thin lines denote regions derived
from CXCR2; a circle denotes the location of the NAA mutation in the
DRY motif. The transfected cells were then assayed for the ability to
support fusion with FIVPET- or FIVGL8-infected
CrFK cells as described above (b). Three fields were counted per well,
each well in duplicate. Results represent the mean
(n = 6) number of syncytia per field ± SE.
feCXCR4, feline CXCR4.
|
|
The ability of CXCR4-transfected cells to support fusion
correlates with the ability to support infection.
The
preceding data demonstrated that the second extracellular loop
of CXCR4 contained the principal determinant for fusion with
FIV-infected cells. We next asked whether the ability of CXCR4-transfected cells to support fusion correlated with the ability to support infection with cell-free virus. CCC-CD4 cells were
transfected with a series of the CXCR4 constructs; expression was
allowed to proceed for 2 days, at which time the cells were infected
with FIVPET or the CXCR4-dependent RF strain of HIV-1. The
cultures were then washed twice and maintained for 7 days, and then the
level of Mg2+-dependent RT activity in the culture
supernatant was quantified. When RT levels were compared, human CXCR4
and the constructs containing the second loop of human CXCR4 (F5H3 and
chimera M) proved the most efficient cofactors for infection with both
FIVPET and HIV-1RF (Fig.
5). Feline CXCR4 and chimera H5F3
containing the second loop of feline CXCR4 functioned less efficiently
for both viruses, while rat CXCR4 and chimera N (containing the second
loop of rat CXCR4) did not differ significantly from the pcDNA3
control. FIVPET used chimera 2444b efficiently for
infection, while HIV-1RF was sensitive to replacement of
the N terminus with that of CXCR2, in agreement with previous findings
(40). Thus, it would appear that the ability of the CXCR4
chimeras to support FIV infection correlates well with fusion assays
between transfected cells and FIV-infected cells and that the second
extracellular loop of human CXCR4 contains the principal determinant of
CXCR4 usage by FIV.

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 5.
Correlation between FIV-mediated cell fusion and virus
infection. CCC-CD4 cells were transfected with a selection of plasmids
which had been shown previously to support FIV-mediated cell fusion.
The cells were then infected with either FIVPET or HIV-1 RF
and assayed for Mg2+-dependent RT activity at 7 days
postinfection. Results are expressed as mean ± SE
(n = 2) and are typical of three separate experiments.
hu- and feCXCR4, human and feline CXCR4.
|
|
 |
DISCUSSION |
In this study, we demonstrated that ectopic expression of CXCR4 on
feline, murine, human, hamster, or mink cells was sufficient to render
the cells permissive for fusion mediated by CrFK-tropic strains of FIV,
suggesting that infection with these strains of virus is analogous to
infection with CD4-independent strains of HIV-2 (20).
Furthermore, human CXCR4 supports both infection and cell fusion with
FIV more efficiently than either feline or rat CXCR4. Using this
property, we demonstrated that the second extracellular loop of CXCR4
contains a critical determinant for the function of CXCR4 as a cofactor
for infection with FIV. These findings are similar to those observed
with HIV-1 LAI/V3-NDK, in which the V3 loop of LAI was replaced with
that of the NDK strain, but differ significantly from those observed
with the parent LAI strain itself (6). The LAI strain of
HIV-1 fused human and rat CXCR4-expressing cells with comparable
efficiencies, whereas the HIV-1 LAI/V3-NDK chimeric virus showed
preferential fusion of cells expressing either human CXCR4 or chimeric
molecules carrying the second extracellular loop of human
CXCR4 in a rat CXCR4 background (6). In a similar study, a
chimeric murine CXCR4 in which the second loop was exchanged with that
of human CXCR4 was found to support infection with the 89.6 strain of
HIV-1 (39) whereas murine CXCR4 itself did not support
infection. In contrast to the LAI and NDK strains of HIV-1, CrFK-tropic
FIV was not sensitive to deletions of the amino-terminal region of CXCR4. In a previous study, the BH8, 89.6, RF, and BK132 strains of
HIV-1 and the SBL6669 strain of HIV-2 were shown to be sensitive to
replacement of the N terminus of CXCR4 with the corresponding domain of
CXCR2 (32). Given that these strains of HIV are CD4 dependent, it is possible that these viruses require an additional interaction with the N terminus of CXCR4 prior to the interaction with
the extracellular loops for fusion to occur.
Chimeras in which either the first or third extracellular loop of CXCR4
was replaced with the corresponding domain of CXCR2 (chimeras 2442, 2242, 4442, and 2244) failed to support cell fusion mediated by FIV.
These data suggest that although the second extracellular loop of CXCR4
is the principal determinant of function as a receptor for FIV, the
adjacent loops either maintain the second loop in the appropriate
conformation for a direct interaction between CXCR4 and the viral
envelope (25) or interact directly themselves with the
envelope glycoprotein. These findings are reminiscent of studies of the
interaction between gibbon ape leukemia virus and feline leukemia virus
subgroup B (FeLV-B) and their receptor Pit1 (8, 49),
amphotropic murine leukemia virus (A-MLV) and Pit2, and ecotropic
murine leukemia virus (E-MLV) and MCAT-1 (1). Chimeric
MCAT-1 receptors constructed between the murine and human MCAT-1
molecules indicated that the third extracellular loop contained the principal determinant of receptor usage by E-MLV (1).
However, the interaction between FeLV-B and A-MLV and Pit1 and Pit2
appears more complex, with recent data suggesting that loops 4 and 5 form the initial binding site for the viral envelope and that a
subsequent interaction with loop 2 is essential for infection
(49). By comparing the interaction between FIV and CXCR4
with the interaction between the mammalian type C retroviruses and
multitransmembrane domain molecules such as Pit1, Pit2, and MCAT-1, it
may be possible to determine whether a common mechanism of interaction
is employed by all retroviruses as has been proposed (49).
While CD4-dependent infection would appear to be the principal
mechanism of infection with HIV and SIV, several examples of CD4-independent infection have been described (10, 26, 36, 50). At present, the role of CD4-independent infection in
the pathogenesis of AIDS remains unclear; however, productive infection of CD4-negative cells has been observed in tissues from HIV-infected individuals (3, 31, 37) and SIV-infected nonhuman primates in advanced disease states (13, 33). The consequences of
high-affinity interactions between the viral envelope glycoprotein and
the chemokine receptor may extend beyond viral tropism. Recent studies
have demonstrated that binding of HIV envelope glycoprotein
to either CXCR4 or CCR5 results in the transduction of a signal
through receptor-coupled G proteins (12). Where binding is
CD4 dependent, the viral envelope may thus mimic the effect of
chemokines on CD4+ cells. However, envelope glycoproteins
of HIV and SIV that interact directly with either CXCR4 (20,
23) or CCR5 (35) in the absence of CD4 have been
identified. It is possible that the envelope glycoproteins from these
viruses have more diverse effects, mimicking the effects of chemokines
on CD4-negative cells such as cells of neuronal origin (23)
and perhaps contributing to the neuropathology associated with AIDS.
The majority of CD4-independent infection appears to occur relatively
inefficiently and is only weakly cytopathic. In contrast, infection
with the HIV-2 strains ROD-B and vcp occurs efficiently on CD4-negative
cell lines (10, 20), while strains such as HIV-2 CBL-22 will
infect efficiently following pretreatment with soluble CD4
(10). The resemblance between CrFK-tropic strains of FIV and
CD4-independent infection with HIV-2 is striking. Adaptation of FIV to
a CrFK-tropic phenotype is accompanied by an increase in charge of the
V3 loop (typically by an E-to-K mutation [46, 52]),
while the Q310K mutation in the V3 loop of HIV-2 ROD-B enhances the
CD4-independent phenotype (44) of the virus. An M751T
mutation in the TM protein of FIV is associated with the CrFK-tropic
phenotype (51), and a similar A526T mutation in the TM
protein of HIV-2 ROD is observed upon adaptation to a CD4-independent phenotype (44); in each case the mutations are located
adjacent to the region of TM thought to be involved in the formation of a coiled-coil domain involved in oligomerization, viral entry, and
neutralization (7, 19, 24, 38, 53). While it is evident that
mutations in other regions of the env gene are required to
confer a CrFK-tropic phenotype on FIV (46, 51, 52) and a
CD4-independent phenotype on HIV-2 (44), the two viruses
adapt similarly to the use of pathways of infection that ultimately result in the use of CXCR4 alone as a viral receptor. Future studies of
infection with CXCR4-independent strains of FIV may provide an insight
into the role of CXCR4-dependent infection in the pathogenesis of AIDS.
It is intriguing that despite the evolutionary divergence between the
amino acid sequences of FIV and HIV, the structure of the envelope
glycoprotein is conserved sufficiently that both viruses can interact
with CXCR4. Moreover, no other human 7TM molecules that we have tested
to date will support fusion mediated by FIV, suggesting that the
interaction is extremely specific. Feline CCR5 failed to support fusion
or infection of CCC-CD4 cells with the CrFK-tropic virus
FIVPET, and preliminary data (not shown) suggest that CCR5
expression alone is insufficient to confer susceptibility to infection
with a primary isolate of FIVGL8 and that CCR5 expression does not correlate with susceptibility to infection with primary isolates of FIV (29). The primary binding receptor for
primary strains of FIV remains to be discovered; until the nature of
this elusive molecule is determined, the role of 7TM molecules in
infection with primary isolates of virus will prove difficult to
resolve. We have found no evidence for inhibition of infection
with primary isolates of FIV by a range of human
-chemokines,
while CrFK infection by FIVPET is inhibited
efficiently by human stromal cell-derived factor 1 (25).
However, until the feline homologs of the
-chemokines are available,
we cannot discount a role for
-chemokine receptors such as CCR5 in
infection with FIV.
 |
ACKNOWLEDGMENTS |
This work was supported by The Wellcome Trust (B.J.W., K.A., and
M.J.H.).
We thank J. H. Elder, D. R. Littman, P. R. Clapham,
T. N. Wells, and J. Hesselgesser for the provision of
reagents and helpful discussions.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Veterinary Pathology, University of Glasgow Veterinary School, Bearsden Rd., Glasgow G61 1QH, United Kingdom. Phone: 44 141 330 3274. Fax: 44 141 330 5602. E-mail: b.willett{at}vet.gla.ac.uk.
 |
REFERENCES |
| 1.
|
Albritton, L. M.,
J. W. Kim,
L. Tseng, and J. M. Cunningham.
1993.
Envelope-binding domain in the cationic amino-acid transporter determines the host range of ecotropic murine retroviruses.
J. Virol.
67:2091-2096[Abstract/Free Full Text].
|
| 2.
|
Alkhatib, G.,
C. Combadiere,
C. C. Broder,
Y. Feng,
P. E. Kennedy,
P. M. Murphy, and E. A. Berger.
1996.
CC CKR5: a RANTES, MIP-1 , MIP-1 receptor as a fusion cofactor for macrophage-tropic HIV-1.
Science
272:1955-1958[Abstract].
|
| 3.
|
Bagasra, O.,
E. Lavi,
L. Bobroski,
K. Khalili,
J. P. Pestaner, and R. Pomerantz.
1996.
Cellular reservoirs of HIV-1 in the central nervous system of HIV-infected individuals: identification by combination of in situ PCR and immunochemistry.
AIDS
10:573-585[Medline].
|
| 4.
|
Berger, E. A.,
R. W. Doms,
E. M. Fenyo,
B. T. M. Korber,
D. R. Littman,
J. P. Moore,
Q. J. Sattentau,
H. Schuitemaker,
J. Sodroski, and R. A. Weiss.
1998.
A new classification for HIV-1.
Nature
391:240[Medline].
|
| 5.
|
Bjorndal, A.,
H. K. Deng,
M. Jansson,
J. R. Fiore,
C. Colognesis,
A. Karlsson,
J. Albert,
G. Scarlatti,
D. R. Littman, and E. M. Fenyo.
1997.
Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype.
J. Virol.
71:7478-7487[Abstract].
|
| 6.
|
Brelot, A.,
N. Heveker,
O. Pleskoff,
N. Sol, and M. Alizon.
1997.
Role of the first and third extracellular domains of CXCR-4 in human immunodeficiency virus coreceptor activity.
J. Virol.
71:4744-4751[Abstract].
|
| 7.
|
Cao, J.,
L. Bergeron,
E. Helseth,
M. Thali,
H. Pepke, and J. Sodroski.
1993.
Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein.
J. Virol.
67:2747-2755[Abstract/Free Full Text].
|
| 8.
|
Chaudry, G. J., and M. V. Eiden.
1997.
Mutational analysis of the proposed gibbon ape leukemia virus binding site in Pit1 suggests that other regions are important for infection.
J. Virol.
71:8078-8081[Abstract].
|
| 9.
|
Choe, H.,
M. Farzan,
Y. Sun,
N. Sullivan,
B. Rollins,
P. D. Ponath,
L. Wu,
C. R. Mackay,
G. LaRosa,
W. Newman,
N. Gerard,
C. Gerard, and J. Sodroski.
1996.
The -chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates.
Cell
85:1135-1148[Medline].
|
| 10.
|
Clapham, P. R.,
A. McKnight, and R. A. Weiss.
1992.
Human immunodeficiency virus type 2 infection and fusion of CD4-negative human cell lines: induction and enhancement by soluble CD4.
J. Virol.
66:3531-3537[Abstract/Free Full Text].
|
| 11.
|
Connor, R. I.,
K. E. Sheridan,
D. Ceradini,
S. Choe, and N. R. Landau.
1997.
Change in coreceptor use correlates with disease progression in HIV-1-infected individuals.
J. Exp. Med.
185:621-628[Abstract/Free Full Text].
|
| 12.
|
Davis, C. B.,
I. Dikic,
D. Unutmaz,
C. M. Hill,
J. Arthos,
M. A. Siani,
D. A. Thompson,
J. Schlessinger, and D. R. Littman.
1997.
Signal transduction due to HIV-1 envelope interactions with chemokine receptors CXCR4 or CCR5.
J. Exp. Med.
186:1793-1798[Abstract/Free Full Text].
|
| 13.
|
Dean, G. A.,
G. H. Reubel,
P. F. Moore, and N. C. Pedersen.
1996.
Proviral burden and infection kinetics of feline immunodeficiency virus in lymphocyte subsets of blood and lymph node.
J. Virol.
70:5165-5169[Abstract/Free Full Text].
|
| 14.
|
de Jong, J. J.,
A. de Ronde,
W. Keulen,
M. Tersmette, and J. Goudsmit.
1992.
Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution.
J. Virol.
66:6777-6780[Abstract/Free Full Text].
|
| 15.
|
Deng, H.,
R. Liu,
W. Ellmeir,
S. Choe,
D. Unutmaz,
M. Burkhart,
P. Di Marzio,
S. Marmon,
R. E. Sutton,
C. M. Hill,
C. B. Davis,
S. C. Peiper,
T. J. Schall,
D. R. Littman, and N. R. Landau.
1996.
Identification of a major co-receptor for primary isolates of HIV-1.
Nature
381:661-666[Medline].
|
| 16.
|
Deng, H. K.,
D. Unutmaz,
V. N. KewalRamani, and D. R. Littman.
1997.
Expression cloning of new receptors used by simian and human immunodeficiency viruses.
Nature
388:296-300[Medline].
|
| 17.
|
Doranz, B. J.,
J. Rucker,
Y. Yi,
R. J. Smyth,
M. Samson,
S. C. Peiper,
M. Parmentier,
R. G. Collman, and R. W. Doms.
1996.
A dual-tropic primary HIV-1 isolate that uses fusin and the -chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion co-factors.
Cell
85:1149-1158[Medline].
|
| 18.
|
Dragic, T.,
T. Litwin,
G. P. Allaway,
S. R. Martin,
Y. Huang,
K. A. Nagashima,
C. Cayanan,
P. J. Maddon,
R. A. Koup,
J. P. Moore, and W. A. Paxton.
1996.
HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR5.
Nature
381:667-673[Medline].
|
| 19.
|
Dubay, J. W.,
S. J. Roberts,
B. Brody, and E. Hunter.
1992.
Mutations in the leucine zipper of the human immunodeficiency virus type 1 transmembrane glycoprotein affect fusion and infectivity.
J. Virol.
66:4748-4756[Abstract/Free Full Text].
|
| 20.
|
Endres, M. J.,
P. R. Clapham,
M. Marsh,
M. Ahuja,
J. D. Turner,
A. McKnight,
J. F. Thomas,
B. Stoebenau-Haggarty,
S. Choe,
P. J. Vance,
T. N. C. Wells,
C. A. Power,
S. S. Sutterwala,
R. W. Doms,
N. R. Landau, and J. A. Hoxie.
1996.
CD4-independent infection by HIV-2 is mediated by fusin.
Cell
87:745-756[Medline].
|
| 21.
|
Feng, Y.,
C. C. Broder,
P. E. Kennedy, and E. A. Berger.
1996.
HIV-1 entry co-factor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor.
Science
272:872-877[Abstract].
|
| 22.
|
Heiber, M.,
A. Marchese,
N. Y. Nguyen,
H. Heng,
S. George, and B. O'Dowd.
1996.
A novel human gene encoding a G-protein-coupled receptor (gpr15) is located on chromosome 3.
Genomics
32:462-465[Medline].
|
| 23.
|
Hesselgesser, J.,
M. HalksMiller,
V. DelVecchio,
S. C. Peiper,
J. Hoxie,
D. L. Kolson,
D. Taub, and R. Horuk.
1997.
CD4-independent association between HIV-1 gp120 and CXCR4: functional chemokine receptors are expressed in human neurons.
Curr. Biol.
7:112-121[Medline].
|
| 24.
|
Ho, D. D.,
M. G. Sarngadharan,
M. S. Hirsch,
R. T. Schooley,
T. R. Rota,
R. C. Kennedy,
T. C. Chanh, and V. L. Sato.
1987.
Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoprotein.
J. Virol.
61:2024-2028[Abstract/Free Full Text].
|
| 25.
|
Hosie, M. J.,
N. Broere,
J. Hesselgesser,
J. D. Turner,
J. A. Hoxie,
J. C. Neil, and B. J. Willett.
1998.
Modulation of feline immunodeficiency virus infection by stromal cell-derived factor.
J. Virol.
72:2097-2104[Abstract/Free Full Text].
|
| 26.
|
Ikeuchi, K.,
S. Kim,
R. A. Byrn,
S. R. Goldring, and J. E. Groopman.
1990.
Infection of nonlymphoid cell by human immunodeficiency virus type 1 or type 2.
J. Virol.
64:4226-4231[Abstract/Free Full Text].
|
| 27.
|
Karlsson, A.,
K. Parsmyr,
E. Sandstrom,
E. M. Fenyo, and J. Albert.
1994.
MT-2 cell tropism as a prognostic marker for disease progression in human immunodeficiency virus type 1 infection.
J. Clin. Microbiol.
32:364-370[Abstract/Free Full Text].
|
| 28.
|
Koot, M.,
I. P. M. Keet,
A. H. V. Vos,
R. E. Y. De Goede,
M. T. L. Roos,
R. A. Coutinho,
F. Miedema,
P. T. A. Schellekens, and M. Tersmette.
1993.
Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS.
Ann. Intern. Med.
118:681-688[Abstract/Free Full Text].
|
| 29.
| Lerner, D. L., and J. H. Elder. 1997. Unpublished data.
|
| 30.
|
Liao, F.,
G. Alkhatib,
K. W. C. Peden,
G. Sharma,
E. A. Berger, and J. M. Farber.
1997.
STRL33, a novel chemokine receptor-like protein, functions as a fusion cofactor for both macrophage-tropic and T cell line-tropic HIV-1.
J. Exp. Med.
185:2015-2023[Abstract/Free Full Text].
|
| 31.
|
Livingstone, W. J.,
M. Moore,
D. Innes,
J. E. Bell,
P. Simmonds,
J. Whitelaw,
R. Wyld,
J. R. Robertson, and R. P. Brettle.
1996.
Frequent infection of peripheral-blood CD8-positive T-lymphocytes with HIV-1.
Lancet
348:649-654[Medline].
|
| 32.
|
Lu, Z. H.,
J. F. Berson,
Y. H. Chen,
J. D. Turner,
T. Y. Zhang,
M. Sharron,
M. H. Jenks,
Z. X. Wang,
J. Kim,
J. Rucker,
J. A. Hoxie,
S. C. Peiper, and R. W. Doms.
1997.
Evolution of HIV-1 coreceptor usage through interactions with distinct CCR5 and CXCR4 domains.
Proc. Natl. Acad. Sci. USA
94:6426-6431[Abstract/Free Full Text].
|
| 33.
|
Mankowski, J. L.,
J. P. Spelman,
H. G. Ressetar,
J. D. Strandberg,
J. Laterra,
D. L. Carter,
J. E. Clements, and M. C. Zink.
1994.
Neurovirulent simian immunodeficiency virus replicates productively in endothelial cells of the central nervous system in vivo and in vitro.
J. Virol.
68:8202-8208[Abstract/Free Full Text].
|
| 34.
|
Marchese, A.,
J. Docherty,
N. Y. Nguyen,
M. Heiber,
R. Cheng,
H. Heng,
L. Tsui,
X. Shi,
S. George, and B. O'Dowd.
1994.
Cloning of human genes encoding novel G protein-coupled receptors.
Genomics
23:609-618[Medline].
|
| 35.
|
Martin, K. A.,
R. Wyatt,
M. Farzan,
H. Choe,
L. Marcon,
E. Desjardins,
J. Robinson,
J. Sodroski,
C. Gerard, and N. P. Gerard.
1997.
CD4-independent binding of SIV gp120 to rhesus CCR5.
Science
278:1470-1473[Abstract/Free Full Text].
|
| 36.
|
McKnight, A.,
P. R. Clapham, and R. A. Weiss.
1994.
HIV-2 and SIV infection of non-primate cell lines expressing human CD4: restrictions to replication at distinct stages.
Virology
201:8-18[Medline].
|
| 37.
|
Moses, A. V.,
F. E. Bloom,
C. D. Pauza, and J. A. Nelson.
1993.
Human immunodeficiency virus infection of human brain capillary endothelial cells occurs via a CD4/galactosylceramide-independent mechanism.
Proc. Natl. Acad. Sci. USA
90:10474-10478[Abstract/Free Full Text].
|
| 38.
|
Muster, T.,
F. Steindl,
M. Purtscher,
A. Trkola,
A. Klima,
G. Himmler,
F. Ruker, and H. Katinger.
1993.
A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1.
J. Virol.
67:6642-6647[Abstract/Free Full Text].
|
| 39.
|
Parolin, C.,
A. Borsetti,
H. Choe,
M. Farzan,
P. Kolchinsky,
M. Heesen,
Q. Ma,
C. Gerard,
G. Palu,
M. E. Dorf,
T. Springer, and J. Sodroski.
1998.
Use of murine CXCR-4 as a second receptor by some T-cell-tropic human immunodeficiency virus.
J. Virol.
72:1652-1656[Abstract/Free Full Text].
|
| 40.
|
Picard, L.,
D. A. Wilkinson,
A. McKnight,
P. W. Gray,
J. A. Hoxie,
P. R. Clapham, and R. A. Weiss.
1997.
Role of the amino-terminal extracellular domain of CXCR-4 in human immunodeficiency virus type 1 entry.
Virology
231:105-111[Medline].
|
| 41.
|
Pleskoff, O.,
C. Treboute,
A. Brelot,
N. Heveker,
M. Seman, and M. Alizon.
1997.
Identification of a chemokine receptor encoded by human cytomegalovirus as a cofactor for HIV-1 entry.
Science
276:1874-1878[Abstract/Free Full Text].
|
| 42.
|
Raport, C. J.,
V. L. Schweickart,
R. L. Eddy,
T. B. Shows, and P. W. Gray.
1995.
The orphan G-protein-coupled receptor-encoding gene V28 is closely related to genes for chemokine receptors and is expressed in lymphoid and neural tissues.
Gene
163:295-299[Medline].
|
| 43.
|
Reeves, J. D.,
A. McKnight,
S. Potempa,
G. Simmons,
P. W. Gray,
C. A. Power,
T. Wells,
R. A. Weiss, and S. J. Talbot.
1997.
CD4-independent infection by HIV-2 (ROD/B): use of the 7-transmembrane receptors CXCR-4, CCR-3, and V28 for entry.
Virology
231:130-134[Medline].
|
| 44.
|
Reeves, J. D., and T. F. Schultz.
1997.
The CD4-independent tropism of human immunodeficiency virus type 2 involves several regions of the envelope protein and correlates with a reduced activation threshold for envelope-mediated fusion.
J. Virol.
71:1453-1465[Abstract].
|
| 45.
|
Schuitemaker, H.,
M. Koot,
N. A. Koostra,
M. W. Dercksen,
R. E. Y. De Goede,
R. P. Van Steenwijk,
J. M. Lange,
J. K. Eeftink Schattenkerk,
F. Miedema, and M. Tersmette.
1992.
Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus populations.
J. Virol.
66:1354-1360[Abstract/Free Full Text].
|
| 46.
|
Siebelink, K. H. J.,
J. A. Karlas,
G. F. Rimmelzwaan,
A. D. M. E. Osterhaus, and M. L. Bosch.
1995.
A determinant of feline immunodeficiency virus involved in CrFK tropism.
Vet. Immunol. Immunopathol.
46:61-69[Medline].
|
| 47.
|
Simmons, G.,
D. Wilkinson,
J. D. Reeves,
M. T. Dittmar,
S. Beddows,
J. Weber,
G. Carnegie,
U. Desselberger,
P. W. Gray,
R. A. Weiss, and P. R. Clapham.
1996.
Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry.
J. Virol.
70:8355-8360[Abstract].
|
| 48.
|
Speck, R. F.,
K. Wehrly,
E. J. Platt,
R. E. Atchison,
I. F. Charo,
D. Kabat,
B. Chesebro, and M. A. Goldsmith.
1997.
Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the V3 loop.
J. Virol.
71:7136-7139[Abstract].
|
| 49.
|
Tailor, C. S., and D. Kabat.
1997.
Variable regions A and B in the envelope glycoproteins of feline leukemia virus subgroup B and amphotropic murine leukemia virus interact with discrete receptor domains.
J. Virol.
71:9383-9391[Abstract].
|
| 50.
|
Tateno, M.,
F. Gonzalez-Scarano, and J. A. Levy.
1989.
The human immunodeficiency virus can infect CD4 human fibroblastoid cells.
Proc. Natl. Acad. Sci. USA
86:4287-4290[Abstract/Free Full Text].
|
| 51.
|
Vahlenkamp, T. W.,
E. J. Verschoor,
N. N. M. P. Schuurman,
A. L. W. van Vliet,
M. C. Horzinek,
H. F. Egberink, and A. de Ronde.
1997.
A single amino acid substitution in the transmembrane envelope glycoprotein of feline immunodeficiency virus alters cellular tropism.
J. Virol.
71:7132-7135[Abstract].
|
| 52.
|
Verschoor, E. J.,
L. A. Boven,
H. Blaak,
A. R. W. van Vliet,
M. C. Horzinek, and A. de Ronde.
1995.
A single mutation within the V3 envelope neutralization domain of feline immunodeficiency virus determines its tropism for CRFK cells.
J. Virol.
69:4752-4757[Abstract].
|
| 53.
|
Wild, C.,
T. Greenwell, and T. Matthew.
1993.
A synthetic peptide from HIV-1 is a potent inhibitor of virus-mediated cell-cell fusion.
AIDS Res. Hum. Retroviruses
9:1051-1053[Medline].
|
| 54.
|
Willett, B. J.,
M. J. Hosie,
J. C. Neil,
J. D. Turner, and J. A. Hoxie.
1997.
Common mechanism of infection by lentiviruses.
Nature
385:587[Medline].
|
| 55.
|
Willett, B. J.,
L. Picard,
M. J. Hosie,
J. D. Turner,
K. Adema, and P. R. Clapham.
1997.
Shared usage of the chemokine receptor CXCR4 by the feline and human immunodeficiency viruses.
J. Virol.
71:6407-6415[Abstract].
|
J Virol, August 1998, p. 6475-6481, Vol. 72, No. 8
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Sundstrom, M., White, R. L., de Parseval, A., Sastry, K. J., Morris, G., Grant, C. K., Elder, J. H.
(2008). Mapping of the CXCR4 Binding Site within Variable Region 3 of the Feline Immunodeficiency Virus Surface Glycoprotein. J. Virol.
82: 9134-9142
[Abstract]
[Full Text]
-
Nolan, K. M., Jordan, A. P. O., Hoxie, J. A.
(2008). Effects of Partial Deletions within the Human Immunodeficiency Virus Type 1 V3 Loop on Coreceptor Tropism and Sensitivity to Entry Inhibitors. J. Virol.
82: 664-673
[Abstract]
[Full Text]
-
Willett, B. J., McMonagle, E. L., Logan, N., Spiller, O. B., Schneider, P., Hosie, M. J.
(2007). Probing the Interaction between Feline Immunodeficiency Virus and CD134 by Using the Novel Monoclonal Antibody 7D6 and the CD134 (Ox40) Ligand. J. Virol.
81: 9665-9679
[Abstract]
[Full Text]
-
Willett, B. J., McMonagle, E. L., Ridha, S., Hosie, M. J.
(2006). Differential Utilization of CD134 as a Functional Receptor by Diverse Strains of Feline Immunodeficiency Virus.. J. Virol.
80: 3386-3394
[Abstract]
[Full Text]
-
de Parseval, A., Ngo, S., Sun, P., Elder, J. H.
(2004). Factors That Increase the Effective Concentration of CXCR4 Dictate Feline Immunodeficiency Virus Tropism and Kinetics of Replication. J. Virol.
78: 9132-9143
[Abstract]
[Full Text]
-
Shimojima, M., Miyazawa, T., Ikeda, Y., McMonagle, E. L., Haining, H., Akashi, H., Takeuchi, Y., Hosie, M. J., Willett, B. J.
(2004). Use of CD134 As a Primary Receptor by the Feline Immunodeficiency Virus. Science
303: 1192-1195
[Abstract]
[Full Text]
-
Lin, G., Baribaud, F., Romano, J., Doms, R. W., Hoxie, J. A.
(2002). Identification of gp120 Binding Sites on CXCR4 by Using CD4-Independent Human Immunodeficiency Virus Type 2 Env Proteins. J. Virol.
77: 931-942
[Abstract]
[Full Text]
-
Willett, B. J., Cannon, C. A., Hosie, M. J.
(2002). Upregulation of Surface Feline CXCR4 Expression following Ectopic Expression of CCR5: Implications for Studies of the Cell Tropism of Feline Immunodeficiency Virus. J. Virol.
76: 9242-9252
[Abstract]
[Full Text]
-
Cormier, E. G., Dragic, T.
(2002). The Crown and Stem of the V3 Loop Play Distinct Roles in Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Interactions with the CCR5 Coreceptor. J. Virol.
76: 8953-8957
[Abstract]
[Full Text]
-
Hosie, M. J., Willett, B. J., Klein, D., Dunsford, T. H., Cannon, C., Shimojima, M., Neil, J. C., Jarrett, O.
(2002). Evolution of Replication Efficiency following Infection with a Molecularly Cloned Feline Immunodeficiency Virus of Low Virulence. J. Virol.
76: 6062-6072
[Abstract]
[Full Text]
-
Baribaud, F., Edwards, T. G., Sharron, M., Brelot, A., Heveker, N., Price, K., Mortari, F., Alizon, M., Tsang, M., Doms, R. W.
(2001). Antigenically Distinct Conformations of CXCR4. J. Virol.
75: 8957-8967
[Abstract]
[Full Text]
-
Dragic, T.
(2001). An overview of the determinants of CCR5 and CXCR4 co-receptor function. J. Gen. Virol.
82: 1807-1814
[Full Text]
-
Vahlenkamp, T. W., De Ronde, A., Schuurman, N. N. M. P., van Vliet, A. L. W., van Drunen, J., Horzinek, M. C., Egberink, H. F.
(1999). Envelope gene sequences encoding variable regions 3 and 4 are involved in macrophage tropism of feline immunodeficiency virus. J. Gen. Virol.
80: 2639-2646
[Abstract]
[Full Text]
-
Egberink, H. F., De Clercq, E., Van Vliet, A. L. W., Balzarini, J., Bridger, G. J., Henson, G., Horzinek, M. C., Schols, D.
(1999). Bicyclams, Selective Antagonists of the Human Chemokine Receptor CXCR4, Potently Inhibit Feline Immunodeficiency Virus Replication. J. Virol.
73: 6346-6352
[Abstract]
[Full Text]
-
Richardson, J., Pancino, G., Merat, R., Leste-Lasserre, T., Moraillon, A., Schneider-Mergener, J., Alizon, M., Sonigo, P., Heveker, N.
(1999). Shared Usage of the Chemokine Receptor CXCR4 by Primary and Laboratory-Adapted Strains of Feline Immunodeficiency Virus. J. Virol.
73: 3661-3671
[Abstract]
[Full Text]
-
Brelot, A., Heveker, N., Adema, K., Hosie, M. J., Willett, B., Alizon, M.
(1999). Effect of Mutations in the Second Extracellular Loop of CXCR4 on Its Utilization by Human and Feline Immunodeficiency Viruses. J. Virol.
73: 2576-2586
[Abstract]
[Full Text]